Big Pharma
12 September 2025 In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
11 September 2025
5 September 2025
4 September 2025
28 August 2025
Latest Features
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
Biotechnology
Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Americas
With growing legislation, research and demand for medical use, cannabis presents an economic opportunity for the Caribbean—but IP rights in the region have some way to go, write Keesha Fleming Lake of Keesha Fleming Lake, and Rachael Lodge Corrie of Foga Daley.
Americas
A patent fee structure being mooted in the US could hurt the innovation economy, especially in industries like biotech and pharma—and will face backlash from businesses, writes Paul Hunter of Foley.
Europe
A new law affecting disputes concerning the ‘Bolar provision’ could allow competitors to enter the Ukrainian market before a patent expires, explains Volodymyr Hrunskyi of Sayenko Kharenko.
Americas
Smaller US companies can now choose to take on much larger, foreign opponents at the ITC, explain Cristen Corry, Paul Ainsworth and Uma Everett of Sterne Kessler.
Americas
Will this year be defined by a concerted shift towards ‘One Health’? Simon Kiddle and Rebecca Tollervey of Mewburn Ellis explore.
Americas
Key developments for the industry this year include a more pro-patent administration and USPTO changes, say Carla Ji-Eun Kim and Deborah Sterling of Sterne Kessler.
More News
15 August 2025 A pair of patents behind an infringement case that proved expensive for Amgen have been found “unenforceable due to inequitable conduct”.
8 August 2025 Payout and licensing deal grants US rights to COVID-19 and flu products | Agreement paves way for BioNTech’s $1.25 billion acquisition of CureVac.
7 August 2025 Captisol dispute intensifies as Italian court sides with Bexson | CyDex claims of trade secret misuse dismissed in early-stage ruling | Case relates to ongoing US dispute.
6 August 2025 With AI accelerating drug development, pharma companies must rethink how they protect models, data, and innovation, say Camille Terfve and Sean Jauss of Mewburn Ellis.
5 August 2025 A much-anticipated referral could upend the EPO’s controversial description amendment rule—and reshape European patent practice, as the Enlarged Board of Appeal prepares to weigh in on G 1/25.
4 August 2025 UK Court of Appeal upholds key Moderna patent against Pfizer and BioNTech | Comirnaty vaccine ruled to infringe European mRNA technology patent.
1 August 2025 German Federal Patent Court invalidates key patent for Xarelto | Bayer faces intensifying generic competition across Europe | Legal team highlights Germany’s crucial role in patent litigation and the importance of stopping early generic entry to protect market exclusivity.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox